{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:12:16Z","timestamp":1790377936309,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.cct.2019.06.007","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T19:27:56Z","timestamp":1561058876000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: Trial design and methodology"],"prefix":"10.1016","volume":"82","author":[{"given":"Heather M.","family":"Choat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail J.","family":"Mick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie E.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert M.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Gerald","family":"McGwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2019.06.007_bb0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2009.21","article-title":"The role of inflammation in insulitis and \u03b2-cell loss in type 1 diabetes","volume":"5","author":"Eizirik","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cct.2019.06.007_bb0010","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1172\/JCI14257","article-title":"Autoimmune type 1 diabetes: resolved and unresolved issues","volume":"108","author":"Notkins","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cct.2019.06.007_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(01)05415-0","article-title":"Type 1 diabetes: new perspectives on disease pathogenesis and treatment","volume":"358","author":"Atkinson","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.cct.2019.06.007_bb0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1463-1326.2008.00941.x","article-title":"Restoring a functional beta-cell mass in diabetes","volume":"4","author":"Pipeleers","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.cct.2019.06.007_bb0025","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s00125-006-0308-2","article-title":"Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes","volume":"49","author":"Meier","year":"2006","journal-title":"Diabetologia."},{"key":"10.1016\/j.cct.2019.06.007_bb0030","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2337\/dc09-0374","article-title":"Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future","volume":"32","author":"Rewers","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cct.2019.06.007_bb0035","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2337\/dc09-0373","article-title":"Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside","volume":"32","author":"Bresson","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cct.2019.06.007_bb0040","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/db10-1810","article-title":"Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes","volume":"60","author":"Greenbaum","year":"2011","journal-title":"Diabetes."},{"key":"10.1016\/j.cct.2019.06.007_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/db10-1114","article-title":"Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man","volume":"60","author":"Skyler","year":"2011","journal-title":"Diabetes."},{"key":"10.1016\/j.cct.2019.06.007_bb0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0959-4388(03)00064-3","article-title":"Modulation of GABAA receptor activity by phosphorylation and receptor trafficking: implications for the efficacy of synaptic inhibition","volume":"13","author":"Kittler","year":"2003","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.cct.2019.06.007_bb0055","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrn919","article-title":"Is there more to GABA than synaptic inhibition?","volume":"3","author":"Owens","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.cct.2019.06.007_bb0060","doi-asserted-by":"crossref","first-page":"11692","DOI":"10.1073\/pnas.1102715108","article-title":"GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes","volume":"108","author":"Soltani","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cct.2019.06.007_bb0065","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.4049\/jimmunol.176.4.2654","article-title":"B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice","volume":"176","author":"Tian","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.cct.2019.06.007_bb0070","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.173.8.5298","article-title":"Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model","volume":"173","author":"Tian","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.cct.2019.06.007_bb0075","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.molimm.2005.07.025","article-title":"Human peripheral blood mononuclear cells express GABAA receptor subunits","volume":"43","author":"Alam","year":"2006","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.cct.2019.06.007_bb0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cmet.2005.11.015","article-title":"Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system","volume":"3","author":"Xu","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.cct.2019.06.007_bb0085","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa0804328","article-title":"GAD treatment and insulin secretion in recent-onset type 1 diabetes","volume":"359","author":"Ludvigsson","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.cct.2019.06.007_bb0090","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cct.2019.06.007_bb0095","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc08-1987","article-title":"New definition for the partial remission period in children and adolescents with type 1 diabetes","volume":"32","author":"Mortensen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cct.2019.06.007_bb0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00125-018-4722-z","article-title":"Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables","volume":"62","author":"Wentworth","year":"2019","journal-title":"Diabetologia."},{"key":"10.1016\/j.cct.2019.06.007_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025338","article-title":"Oral treatment with gamma-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice","volume":"6","author":"Tian","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2019.06.007_bb0110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","article-title":"Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial","volume":"378","author":"Sherry","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.cct.2019.06.007_bb0115","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2337\/dc14-2707","article-title":"Alternate approaches for Pediatric type 1 diabetes drug development and potential regulatory approval: a perspective","volume":"38","author":"Turner","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cct.2019.06.007_bb0120","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.2337\/db11-1538","article-title":"Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data","volume":"61","author":"Greenbaum","year":"2012","journal-title":"Diabetes."},{"key":"10.1016\/j.cct.2019.06.007_bb0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2337\/dc12-0836","article-title":"Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes","volume":"36","author":"Besser","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cct.2019.06.007_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2015.00260","article-title":"Study of GABA in healthy volunteers: pharmacokinetics and pharmacodynamics","volume":"6","author":"Li","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cct.2019.06.007_bb0135","series-title":"Guidance for Industry: Estimating the Maximum Safe Starting Dose in Adult Healthy Volunteer, Appendix B","author":"USFDA","year":"2005"},{"key":"10.1016\/j.cct.2019.06.007_bb0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1740774513510070","article-title":"Recruitment and retention of participants for an international type 1 diabetes prevention trial: A coordinators\u2019 perspective","volume":"11","author":"Franciscus","year":"2014","journal-title":"Clin. Trials"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714419300102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714419300102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T19:07:33Z","timestamp":1561748853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714419300102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":28,"alternative-id":["S1551714419300102"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2019.06.007","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: Trial design and methodology","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2019.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}